Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $20.91: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 6.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum.
Syndax Pharmaceuticals is a commercial-stage oncology company with two FDA-approved products: Revuforj (revumenib, for R/R acute leukemia with KMT2A translocation or NPM1m AML, approved Nov 2024 and Oct 2025) and Niktimvo (axatilimab, for cGVHD after 2+ prior lines, approved Aug... Read more
Sell if holding. Engine safety override at $20.91: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 6.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.8/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 0d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductRevuforj10-K Item 1A: 'Our business currently depends heavily on our ability to successfully commercialize Revuforj in the United States'
- HIGHSupplierIncyte10-K Item 1A: 'We are dependent upon our collaboration with Incyte to further develop and commercialize axatilimab'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $20.91: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 6.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $19.76. Score 4.8/10, moderate confidence.
Take-profit target: $34.37 (+64.1% upside). Prior stop was $19.76. Stop-loss: $19.76.
Concentration risk — Product: Revuforj; Concentration risk — Supplier: Incyte; Quality below floor (2.8 < 4.0).
Syndax Pharmaceuticals, Inc. trades at a P/E of N/A (forward -82.3). TrendMatrix value score: 6.6/10. Verdict: Sell.
20 analysts cover SNDX with a consensus score of 4.3/5. Average price target: $40.
What does Syndax Pharmaceuticals, Inc. do?Syndax Pharmaceuticals is a commercial-stage oncology company with two FDA-approved products: Revuforj (revumenib, for...
Syndax Pharmaceuticals is a commercial-stage oncology company with two FDA-approved products: Revuforj (revumenib, for R/R acute leukemia with KMT2A translocation or NPM1m AML, approved Nov 2024 and Oct 2025) and Niktimvo (axatilimab, for cGVHD after 2+ prior lines, approved Aug 2024 in partnership with Incyte).